Latest Medicinova (MNOV) Headlines Canadian For
Post# of 68
Posted On: 03/13/2014 11:13:34 AM
Latest Medicinova (MNOV) Headlines
Canadian Forex Review: C$ Lower Ahead of BoC Announcement
Commodity News Service Canada - Commodity News Service Canada, Inc. - Tue Mar 04, 3:46PM CST
The Canadian dollar closed lower on Tuesday, undermined by positioning ahead of Wednesday's Bank of Canada policy announcement, analysts said.
Five Worst, Pandering Drug Stocks of J.P. Morgan Healthcare Confab Week
at The Street - Fri Jan 17, 2:52PM CST
The drug companies on this list issued the most ridiculous, stock-touting press releases, all seeking to glom onto the excitement of the JPM healthcare conference.
Nasdaq stocks posting largest volume increases
AP - Wed Jan 15, 5:06PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
MediciNova Announces Positive Results in NASH Mouse Model With MN-001 and Prepares to Initiate Phase 2 Trial in the U.S.
GlobeNewswire - Tue Jan 14, 7:00AM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive results from a study that examined the potential clinical efficacy of MN-001 for the treatment of NASH (nonalcoholic steatohepatitis).
MediciNova (MNOV) Jumps: Stock Adds 22.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 13, 6:51AM CST
MediciNova Inc. was a big mover last session, as its shares rose over 22% on the day.
MediciNova Inc wins new patent for MN-221 for irritable bowel syndrome
M2 - Tue Nov 12, 8:07AM CST
Biopharmaceutical company MediciNova Inc (NASDAQ GM:MNOV) on Monday reported the receipt of the new US patent for MN-221 for the treatment of irritable bowel syndrome.
MediciNova Receives New Patent Covering MN-221 in Irritable Bowel Syndrome
GlobeNewswire - Mon Nov 11, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Tokyo Stock Exchange (Code Number: 4875), announced that a new U.S. patent has been granted which covers MN-221 in the treatment of irritable bowel syndrome.
MediciNova Reports Third Quarter 2013 Results
GlobeNewswire - Thu Nov 07, 5:30PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Tokyo Stock Exchange (Code Number:4875), today announced financial results for the third quarter ended September 30, 2013.
MediciNova Inc elects Geoffrey O'Brien as VP
M2 - Thu Oct 17, 5:46AM CDT
Biopharmaceutical company MediciNova Inc (NasdaqGM:MNOV) revealed on Wednesday the addition of Geoffrey O'Brien, J.D./M.B.A. as its vice president.
MediciNova Inc hires Yutaka Kobayashi to board
M2 - Thu Oct 17, 4:54AM CDT
Biopharmaceutical company MediciNova Inc (NasdaqGM:MNOV) revealed on Wednesday the addition of Yutaka Kobayashi to its board of directors.
MediciNova Appoints Yutaka Kobayashi to Its Board of Directors
GlobeNewswire - Wed Oct 16, 4:00PM CDT
MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the appointment of Mr. Yutaka Kobayashi to its Board of Directors.
MediciNova Appoints Geoffrey O'Brien as Vice President
GlobeNewswire - Wed Oct 16, 3:30PM CDT
MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the appointment of Geoffrey O'Brien, J.D./M.B.A. as Vice President.
MediciNova Inc awarded Notice of Allowance for new patent covering MN-029 in development for treatment of solid tumor cancers
M2 - Mon Oct 07, 5:01AM CDT
Biopharmaceutical company MediciNov Inc (NASDAQ Global Market:MNOV) reported on Sunday the receipt of a Notice of Allowance from the US Patent and Trademark Office for a pending patent application that covers MN-029 (denibulin) di-hydrochloride.
MediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride
GlobeNewswire - Sun Oct 06, 6:00PM CDT
MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Tokyo Stock Exchange (Code Number: 4875), announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-029 (denibulin) di-hydrochloride.
MediciNova Inc to launch clinical trial of MN-166 (ibudilast) for alcohol dependence, with funding from NIAAA
M2 - Mon Aug 26, 10:43AM CDT
Biopharmaceutical company MediciNova Inc (NASDAQ GM:MNOV) said on Sunday that its clinical trial of MN-166 (ibudilast) for alcohol dependence will be funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health.
National Institute on Alcohol Abuse and Alcoholism Funds New UCLA Clinical Trial of MediciNova's MN-166 in Treating Alcoholism
GlobeNewswire - Sun Aug 25, 6:00PM CDT
The University of California, Los Angeles' (UCLA's) Departments of Psychology, and Psychiatry and Biobehavioral Sciences Brain Research Institute, and MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced that the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health, will fund a clinical trial of MN-166 (ibudilast) for alcohol dependence. The proposed trial has also completed FDA review. MediciNova previously announced an ongoing Phase 2a trial of MN-166 in opioid dependence with Columbia University investigators, and a UCLA Phase 2b trial in methamphetamine dependence anticipated to initiate enrollment later this quarter - both funded by the National Institutes of Drug Abuse (NIDA).
MediciNova Inc posts higher net loss of USD2.8m for Q2 2013
M2 - Fri Aug 09, 4:13AM CDT
Biopharmaceutical company MediciNova Inc (NASDAQ GM:MNOV) stated on Thursday its net loss of USD2.8m (USD0.14 per share) for the second quarter ended 30 June 2013.
MediciNova Reports Second Quarter 2013 Results
GlobeNewswire - Thu Aug 08, 4:30PM CDT
MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for the second quarter ended June 30, 2013 through the filing of its quarterly report on Form 10-Q.
ATSG, NOA, MNOV, USAT, GLUU, OPTT Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Fri Jul 19, 5:09AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Air Transport Services Group Inc (NASDAQ:ATSG), North American Energy Partners Inc (NYSE:NOA), MediciNova Inc (NASDAQ:MNOV), USA Technologies Inc (NASDAQ:USAT), Glu Mobile Inc (NASDAQ:GLUU), Ocean Power Technologies Inc (NASDAQ:OPTT) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
Canadian Forex Review: C$ Lower Ahead of BoC Announcement
Commodity News Service Canada - Commodity News Service Canada, Inc. - Tue Mar 04, 3:46PM CST
The Canadian dollar closed lower on Tuesday, undermined by positioning ahead of Wednesday's Bank of Canada policy announcement, analysts said.
Five Worst, Pandering Drug Stocks of J.P. Morgan Healthcare Confab Week
at The Street - Fri Jan 17, 2:52PM CST
The drug companies on this list issued the most ridiculous, stock-touting press releases, all seeking to glom onto the excitement of the JPM healthcare conference.
Nasdaq stocks posting largest volume increases
AP - Wed Jan 15, 5:06PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
MediciNova Announces Positive Results in NASH Mouse Model With MN-001 and Prepares to Initiate Phase 2 Trial in the U.S.
GlobeNewswire - Tue Jan 14, 7:00AM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive results from a study that examined the potential clinical efficacy of MN-001 for the treatment of NASH (nonalcoholic steatohepatitis).
MediciNova (MNOV) Jumps: Stock Adds 22.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 13, 6:51AM CST
MediciNova Inc. was a big mover last session, as its shares rose over 22% on the day.
MediciNova Inc wins new patent for MN-221 for irritable bowel syndrome
M2 - Tue Nov 12, 8:07AM CST
Biopharmaceutical company MediciNova Inc (NASDAQ GM:MNOV) on Monday reported the receipt of the new US patent for MN-221 for the treatment of irritable bowel syndrome.
MediciNova Receives New Patent Covering MN-221 in Irritable Bowel Syndrome
GlobeNewswire - Mon Nov 11, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Tokyo Stock Exchange (Code Number: 4875), announced that a new U.S. patent has been granted which covers MN-221 in the treatment of irritable bowel syndrome.
MediciNova Reports Third Quarter 2013 Results
GlobeNewswire - Thu Nov 07, 5:30PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Tokyo Stock Exchange (Code Number:4875), today announced financial results for the third quarter ended September 30, 2013.
MediciNova Inc elects Geoffrey O'Brien as VP
M2 - Thu Oct 17, 5:46AM CDT
Biopharmaceutical company MediciNova Inc (NasdaqGM:MNOV) revealed on Wednesday the addition of Geoffrey O'Brien, J.D./M.B.A. as its vice president.
MediciNova Inc hires Yutaka Kobayashi to board
M2 - Thu Oct 17, 4:54AM CDT
Biopharmaceutical company MediciNova Inc (NasdaqGM:MNOV) revealed on Wednesday the addition of Yutaka Kobayashi to its board of directors.
MediciNova Appoints Yutaka Kobayashi to Its Board of Directors
GlobeNewswire - Wed Oct 16, 4:00PM CDT
MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the appointment of Mr. Yutaka Kobayashi to its Board of Directors.
MediciNova Appoints Geoffrey O'Brien as Vice President
GlobeNewswire - Wed Oct 16, 3:30PM CDT
MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the appointment of Geoffrey O'Brien, J.D./M.B.A. as Vice President.
MediciNova Inc awarded Notice of Allowance for new patent covering MN-029 in development for treatment of solid tumor cancers
M2 - Mon Oct 07, 5:01AM CDT
Biopharmaceutical company MediciNov Inc (NASDAQ Global Market:MNOV) reported on Sunday the receipt of a Notice of Allowance from the US Patent and Trademark Office for a pending patent application that covers MN-029 (denibulin) di-hydrochloride.
MediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride
GlobeNewswire - Sun Oct 06, 6:00PM CDT
MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Tokyo Stock Exchange (Code Number: 4875), announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-029 (denibulin) di-hydrochloride.
MediciNova Inc to launch clinical trial of MN-166 (ibudilast) for alcohol dependence, with funding from NIAAA
M2 - Mon Aug 26, 10:43AM CDT
Biopharmaceutical company MediciNova Inc (NASDAQ GM:MNOV) said on Sunday that its clinical trial of MN-166 (ibudilast) for alcohol dependence will be funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health.
National Institute on Alcohol Abuse and Alcoholism Funds New UCLA Clinical Trial of MediciNova's MN-166 in Treating Alcoholism
GlobeNewswire - Sun Aug 25, 6:00PM CDT
The University of California, Los Angeles' (UCLA's) Departments of Psychology, and Psychiatry and Biobehavioral Sciences Brain Research Institute, and MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced that the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health, will fund a clinical trial of MN-166 (ibudilast) for alcohol dependence. The proposed trial has also completed FDA review. MediciNova previously announced an ongoing Phase 2a trial of MN-166 in opioid dependence with Columbia University investigators, and a UCLA Phase 2b trial in methamphetamine dependence anticipated to initiate enrollment later this quarter - both funded by the National Institutes of Drug Abuse (NIDA).
MediciNova Inc posts higher net loss of USD2.8m for Q2 2013
M2 - Fri Aug 09, 4:13AM CDT
Biopharmaceutical company MediciNova Inc (NASDAQ GM:MNOV) stated on Thursday its net loss of USD2.8m (USD0.14 per share) for the second quarter ended 30 June 2013.
MediciNova Reports Second Quarter 2013 Results
GlobeNewswire - Thu Aug 08, 4:30PM CDT
MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for the second quarter ended June 30, 2013 through the filing of its quarterly report on Form 10-Q.
ATSG, NOA, MNOV, USAT, GLUU, OPTT Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Fri Jul 19, 5:09AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Air Transport Services Group Inc (NASDAQ:ATSG), North American Energy Partners Inc (NYSE:NOA), MediciNova Inc (NASDAQ:MNOV), USA Technologies Inc (NASDAQ:USAT), Glu Mobile Inc (NASDAQ:GLUU), Ocean Power Technologies Inc (NASDAQ:OPTT) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
(0)
(0)